Saturday 17 October 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.6% and free cash flow grew 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.73
0.00
0.00%
Follow CGTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 4.68 | 1.07 | 0.90 | 0.34 | 0.22 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 13.80 | 7.30 | 3.49 | 2.95 | 3.83 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 21 | 25 | 28 | 28 | 14 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (5) | (8) | (12) | (21) | (26) | (34) | (23) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (5) | (8) | (12) | (21) | (26) | (34) | (23) | |||||
| Depreciation | — | — | — | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.40) | (15.43) | (3.13) | (0.91) | (0.86) | (0.86) | (0.32) | |||||
| Cash flow | — | — | — | (0.14) | (6.76) | (0.70) | (0.78) | (0.53) | (0.72) | (0.34) | |||||
| Capex | — | — | — | 0.00 | (0.02) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.14) | (6.78) | (0.70) | (0.79) | (0.54) | (0.72) | (0.34) | |||||
| Book value | — | — | — | (2.66) | (25.22) | 9.88 | 1.70 | 0.82 | 0.47 | 0.47 | |||||
| Shares, m | — | — | — | 22 | 1 | 5 | 24 | 30 | 40 | 73 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (3) | (4) | (19) | (16) | (28) | (25) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (3) | (3) | (4) | (19) | (16) | (28) | (25) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 3 | 4 | 51 | 40 | 24 | 18 | 34 | ||||
| Total debt | — | — | — | 60 | 13 | — | 2 | — | — | — | |||||
| Net debt | — | — | — | 57 | 8 | (55) | (42) | (30) | (25) | (37) | |||||
| Shareholders’ equity | — | — | — | (58) | (13) | 51 | 40 | 24 | 19 | 34 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (234.94) | (165.63) | (49.05) | (39.06) | (60.26) | (103.89) | (59.75) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 13.84 | 19.07 | 192.16 | (46.76) | (79.69) | (157.19) | (88.60) | |||||
Negative figures in brackets.
Charts ten years each
Cognition Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PDSB PDS Biotechnology Corporation | $72.8M | — (loss-making) | — | — | n/m | +69.32% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HRTX Heron Therapeutics, Inc. | $71.5M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| MNOV MediciNova, Inc. | $71.4M | — (loss-making) | — (loss-making) | +240.56% (above 0%: growing) | n/m | +16.75% (above 0%: growing) | 69.33% | (554.36%) | Compare |
| CGTX Cognition Therapeutics, Inc. | $69.7M | — (loss-making) | — | — | n/m | +45.35% (above 0%: growing) | 0.00% | 0.00% | |
| MAIA MAIA Biotechnology, Inc. | $69.2M | — (loss-making) | — | — | n/m | −63.23% (below 0%: shrinking) | — | 0.00% | Compare |
| CSBR Champions Oncology, Inc. | $66.7M | — (loss-making) | — (loss-making) | +8.84% (above 0%: growing) | n/m | −198.74% (below 0%: shrinking) | 50.54% | (2.69%) | Compare |
| OSTX OS Therapies Incorporated | $66.0M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| HYFT MindWalk Holdings Corp. | $66.0M | — (loss-making) | — (loss-making) | +19.37% (above 0%: growing) | n/m | +9.79% (above 0%: growing) | 58.58% | (159.86%) | Compare |
| NMAD Nomad Power Solutions, Inc. | $65.9M | — (loss-making) | — | — | n/m | −230.63% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $67.9M | — | — | +14.11% | — | −26.72% | 58.58% | (1.34%) |
Cognition Therapeutics, Inc. (CGTX) key facts
- Cognition Therapeutics, Inc. (CGTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CGTX traded at $0.73, a market capitalization of $69.7 million.
- Return on equity was −88.6% and debt-to-equity 0.00.
Cognition Therapeutics, Inc. (CGTX) Latest News
No news at this impact. Lower the threshold for more.